| Literature DB >> 9973531 |
M Ichikawa1, C S Koh, Y Inaba, C Seki, A Inoue, M Itoh, Y Ishihara, C C Bernard, A Komiyama.
Abstract
We have recently shown that a single dose of the myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 produces a relapsing-remitting demyelinating disease similar to multiple sclerosis (MS) in Lewis rats. In this study we have assessed the possibility that a subclass of anti-MOG35-55 antibodies influences the clinical outcome of these diseases by examining the classes and isotypes of anti-MOG35-55 antibody produced during the course of MOG35-55-induced demyelinating disease in NOD mice. Following immunization, 7 of the 21 injected mice had only mild diseases, while the 14 others had severe progressive and/or relapsing-remitting diseases. There were no differences in anti-MOG35-55 IgG, IgA, IgM, IgG1, IgG2a, and IgG3 antibody titers between the severe and mild symptoms groups. High levels of IgG2b antibody to MOG35-55 were detected in all mice with severe symptoms. In contrast, none of the mice which contracted a mild disease produced anti-MOG35-55 IgG2b. These results suggest that in NOD mice, the IgG2b antibody response to MOG35-55 is associated with the severity of this MS-like demyelinating disease. Copyright 1999 Academic Press.Entities:
Mesh:
Substances:
Year: 1999 PMID: 9973531 DOI: 10.1006/cimm.1998.1414
Source DB: PubMed Journal: Cell Immunol ISSN: 0008-8749 Impact factor: 4.868